Browsing by Author "Le Corre Pérez, Monique Nicole"

Now showing 1 - 15 of 15
  • Thumbnail Image
    Item
    A Single-Nucleotide Polymorphism of (V3) Integrin Is Associated with the Andes Virus Infection Susceptibility
    (2019) Martinez Valdebenito, Constanza Pamela; Angulo Troncoso Jenniffer Alexandra; Le Corre Pérez, Monique Nicole; Marco Caceres, Claudia Alejandra; Vial, Cecilia; Miquel Poblete, Juan Francisco; Cerda Lorca, Jaime Rodrigo; Mertz, Gregory; Vial, Pablo; Lopez Lastra, Marcelo Andres; Ferres Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Caracterización clínica y epidemiológica de infección asociada a atención en salud por virus influenza en pacientes críticos
    (2019) Gutiérrez, Valentina; Cerda, Jaime; Le Corre Pérez, Monique Nicole; Medina, Rafael; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Emergent Pneumonia in Children
    (2021) Perret Pérez, Cecilia; Le Corre Pérez, Monique Nicole; Castro Rodríguez, Jose A.
    In recent decades there have been multiple pathogens, viruses and bacteria, which have emerged as causal agents of pneumonia affecting adults, albeit less frequently, to children. For the purposes of this article we have classified emerging pathogens as follows: True emerging, to pathogens identified for the very first time affecting human population (SARS-CoV-1, SARS-CoV-2, MERS-CoV, avian influenza, and hantavirus); Re-emerging, to known pathogens which circulation was controlled once, but they have reappeared (measles, tuberculosis, antimicrobial resistant bacteria such as CA-MRSA, Mycoplasma pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and new serotypes of post-vaccine pneumococcal); and finally, those that we have called old known with new presentations, including common pathogens that, in particular condition, have changed their form of presentation (rhinovirus, and non-SARS coronavirus). We will review for each of them their epidemiology, forms of presentation, therapy, and prognosis in children compared to the adult with the aim of being able to recognize them to establish appropriate therapy, prognostics, and effective control measures.
  • Thumbnail Image
    Item
    Endocarditis por Streptococcus pneumoniae en niños. Presentación de un caso clínico y revisión de la literatura
    (2005) Le Corre Pérez, Monique Nicole; Viviani Salgado, Tamara Nieves; Perret Pérez, Cecilia; Prado Sanhueza, Maria Alejandra
    La endocarditis causada por Streptococcus pneumoniae es una patología muy poco frecuente en niños, correspondiendo sólo a 3 - 7% de los casos. Sin embargo, su importancia radica en que se puede presentar de forma muy agresiva, con complicaciones como destrucción valvular y abscesos, y con una mortalidad reportada hasta 61%, de no mediar tratamiento antimicrobiano precoz y muchas veces cardiocirugía. En más del 50% se puede asociar a otros focos infecciosos, como meningitis, neumonía, sinusitis o mastoiditis. Se describe el caso de una lactante de 10 meses que presentó una meningitis asociada a endocarditis debidas a S. pneumoniae, con grave compromiso cardíaco, y que requirió reemplazo valvular. Se realizó una revisión de la literatura médica acerca de endocarditis por S. pneumoniae en niños.
  • No Thumbnail Available
    Item
    Hantavirus in humans: a review of clinical aspects and management
    (2023) Vial Clavo, Pablo Agustín; Ferrés, Marcela; Vial, Cecilia; Klingstrom, Jonás; Ahlm, Clas; López, René; Le Corre Pérez, Monique Nicole; Mertz J., Gregory
    Hantavirus infections are part of the broad group of viral haemorrhagic fevers. They are also recognised as a distinct model of an emergent zoonotic infection with a global distribution. Many factors influence their epidemiology and transmission, such as climate, environment, social development, ecology of rodent hosts, and human behaviour in endemic regions. Transmission to humans occurs by exposure to infected rodents in endemic areas; however, Andes hantavirus is unique in that it can be transmitted from person to person. As hantaviruses target endothelial cells, they can affect diverse organ systems; increased vascular permeability is central to pathogenesis. The main clinical syndromes associated with hantaviruses are haemorrhagic fever with renal syndrome (HFRS), which is endemic in Europe and Asia, and hantavirus cardiopulmonary syndrome (HCPS), which is endemic in the Americas. HCPS and HFRS are separate clinical entities, but they share several features and have many overlapping symptoms, signs, and pathogenic alterations. For HCPS in particular, clinical outcomes are highly associated with early clinical suspicion, access to rapid diagnostic testing or algorithms for presumptive diagnosis, and prompt transfer to a facility with critical care units. No specific effective antiviral treatment is available.
  • No Thumbnail Available
    Item
    Human metapneumovirus as hospitalization cause in children under 3 years old with acute respiratory infections during 2004
    (2007) Prado Sanhueza, Maria Alejandra; Perret Pérez, Cecilia; Montecinos Perret, Luisa Paola; Veloz B., A.; Le Corre Pérez, Monique Nicole; Habash A., L.; Potin Santander, Marcela Patricia; Abarca Villaseca, Katia; Ferres Garrido, Marcela Viviana
    Metapneumovirus humano (MPVh) fue detectado entre julio y noviembre en 15 de 123 niños bajo 3 años de edad hospitalizados por infección respiratoria aguda (12%). Las muestras fueron estudiadas mediante técnicas de biología molecular (RPC-TR de muestra de hisopado nasofaríngeo y/o de sobrenadante de cultivo). El 67% de los niños hospitalizados con MPVh tenían menos de 1 año de edad, todos ellos presentaron tos y fiebre y el principal motivo de hospitalización fue el requerimiento de oxígeno en 73% de los casos. Si bien un tercio de los pacientes tenía patología previa, su evolución clínica no fue diferente respecto de los niños previamente sanos. El patrón radiológico mostró aumento de la trama intersticial, con focos de consolidación en 6 casos (40%). El diagnóstico más frecuente fue síndrome bronquial obstructivo o bronquiolitis, asociado o no a neumonía. Destaca la necesidad de un método de diagnóstico rápido para optimizar el diagnóstico diferencial, manejo y control de infecciones en estos pacientes.
  • No Thumbnail Available
    Item
    Humoral immune-response to a SARS-CoV-2- BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine
    (BMJ PUBLISHING GROUP, 2022) Durán Santa Cruz, Josefina Gracia; Burgos Cañete, Paula Isabel; Le Corre Pérez, Monique Nicole; Ruiz-Tagle, Cinthya; Martínez Valdebenito, Constanza; Castro, Mauricio; Metcalfe Torres, Valentina Estrella; Niemann Concha, Paula Valentina; Balcells Marty, María Elvira
  • Thumbnail Image
    Item
    Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents
    (Frontiers Media SA, 2024) Rivera Pérez, Daniela; Méndez Vejar, Constanza Soledad; Diethelm Varela, Benjamín Manuel; Melo González, Felipe Andrés; Vázquez Hernández, Yaneisi; Meng, Xing; Xin, Qianqian; Fasce, Rodrigo A.; Fernández, Jorge; Mora, Judith; Ramírez, Eugenio; Acevedo, Mónica L.; Valiente Echeverria, Fernando; Soto Rifo, Ricardo; Grifoni, Alba; Weiskopf, Daniela; Sette, Alessandro; Astudillo Paredes, Patricio Andrés; Le Corre Pérez, Monique Nicole; Abarca Villaseca, Katia; Perret Pérez, Cecilia; González Muñoz, Pablo Alberto; Soto Ramírez, Jorge Andrés; Bueno Ramírez, Susan; Kalergis, Alexis M.
    Background: Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of the Omicron variant, its subvariants, and the immune response dynamics of the naturally infected with the virus. Methods: Twelve subjects between 3-17 years old (yo), vaccinated with two doses of CoronaVac®, were followed and diagnosed as breakthrough cases starting 14 days after receiving the second dose. Total IgGs against different SARS-CoV-2 proteins and the neutralizing capacity of these antibodies after infection were measured in plasma. The activation of CD4+ and CD8+ T cells was evaluated in peripheral blood mononuclear cells stimulated with peptides derived from the proteins from the wild-type (WT) virus and Omicron subvariants by flow cytometry, as well as different cytokines secretion by a Multiplex assay. Results: 2 to 8 weeks post-infection, compared to 4 weeks after 2nd dose of vaccine, there was a 146.5-fold increase in neutralizing antibody titers against Omicron and a 38.7-fold increase against WT SARS-CoV-2. Subjects showed an increase in total IgG levels against the S1, N, M, and NSP8 proteins of the WT virus. Activated CD4+ T cells showed a significant increase in response to the BA.2 subvariant (p<0.001). Finally, the secretion of IL-2 and IFN-γ cytokines showed a discreet decrease trend after infection in some subjects. Conclusion: SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine produced an increase in neutralizing antibodies against Omicron and increased specific IgG antibodies for different SARS-CoV-2 proteins. CD4+ T cell activation was also increased, suggesting a conserved cellular response against the Omicron subvariants, whereas Th1-type cytokine secretion tended to decrease. Clinical Trial Registration: clinicaltrials.gov #NCT04992260
  • Thumbnail Image
    Item
    Infecciones osteoarticulares en población pediátrica: clínica y microbiología de los últimos 15 años
    (2022) Cañete Campos, Ismael Ignacio; Moller Macherone, Francesca Andrea; Figueroa Gatica, María Jesús; Monge Iriarte, Marcela María; Le Corre Pérez, Monique Nicole; Vizcaya Altamirano, María Cecilia; Hodgson Ovalle, Felipe Andrés; Ibáñez León, María Angélica
    Resumen Introducción: El diagnóstico y tratamiento oportuno de las infec- ciones osteoarticulares (IOA) pediátricas son imperativos para evitar complicaciones y secuelas, siendo relevante conocer la microbiología local. Objetivo: Describir las características de las IOA pediátricas tratadas en nuestro centro. Pacientes y Métodos: Estudio observacional descriptivo. Se analizaron pacientes bajo 15 años de edad tratados por IOA entre los años 2004 y 2020. Se evaluaron características clínicas, de laboratorio, microbiología y tratamiento. Resultados: Se incluyeron 126 pacientes (63,5% hombres), con una mediana de edad de 5,09 años (rango: 0,5-14,6 años); 61,1% artritis séptica (AS), 38,9% osteomielitis (OM). Un 92,9% presentó dolor y 68,3% fiebre. La localización más frecuente en AS fue rodilla (33,7%) y en OM tibia (30,6%) y fémur (30,6%). Se identificó agente en 77 pacientes (61,1%), siendo más frecuentes Staphylococcus aureus (n = 44), Kingella kingae (n = 13) y Streptococcus pyogenes (n = 8). Los cuatro pacientes con reacción de polimerasa en cadena (RPC) universal positiva para K. kingae no fueron detectados por otros métodos. Conclusión: El agente más frecuente sigue siendo S. aureus, observándose un aumento en la resistencia de éste en comparación con series nacionales anteriores, y, por primera vez en nuestro medio, se comunica la detección de K. kingae, específicamente relacionada al uso de técnicas moleculares. Palabras clave: Infecciones osteoarticulares; osteomielitis; artritis séptica; pediatría; diagnóstico.
  • Thumbnail Image
    Item
    Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
    (2021) Beltrán Pavez, Carolina; Riquelme Barrios, Sebastián; Oyarzún Arrau, Aarón; Gaete Argel, Aracelly; González Stegmaier, Roxana; Cereceda Solis, Karina; Aguirre, Adam; Travisany, Dante; Palma Vejares, Ricardo; Barriga, Gonzalo P.; Gaggero, Aldo; Martínez Valdebenito, Constanza; Le Corre Pérez, Monique Nicole; Ferrés, Marcela; Balcells Marty, María Elvira; Fernández, Jorge; Ramírez, Eugenio; Villarroel, Franz; Valiente Echeverría, Fernando; Soto Rifo, Ricardo
    Chile has one of the worst numbers worldwide in terms of SARS-CoV-2 positive cases and COVID-19-related deaths per million inhabitants; thus, characterization of neutralizing antibody (NAb) responses in the general population is critical to understanding of immunity at the local level. Given our inability to perform massive classical neutralization assays due to the scarce availability of BSL-3 facilities in the country, we developed and fully characterized an HIV-based SARS-CoV-2 pseudotype, which was used in a 96-well plate format to investigate NAb responses in samples from individuals exposed to SARS-CoV-2 or treated with convalescent plasma. We also identified samples with decreased or enhanced neutralization activity against the D614G spike variant compared with the wild type, indicating the relevance of this variant in host immunity. The data presented here represent the first insights into NAb responses in individuals from Chile, serving as a guide for future studies in the country.
  • Thumbnail Image
    Item
    Mother-to-child transmission of Andes virus through breast milk, Chile
    (2020) Ferrés, Marcela; Martínez Valdebenito, Constanza; Angulo, J.; Henríquez, C.; Vera Otarola, Jorge Andrés; Vergara, M. J.; Vial Cox, María Cecilia; Vial Claro, Pablo; Pérez, J.; Le Corre Pérez, Monique Nicole; Fernández, J.; Sotomayor, V.; Valdés, M. F.; González-Candia, D.; Tischler, N. D.; Mertz, G.
  • Thumbnail Image
    Item
    Parotiditis en Chile: caracterización clínica y molecular de dos casos en una población altamente inmunizada
    (2018) Le Corre Pérez, Monique Nicole; Barria, S.; Lopez, T.; Martinez Valdebenito, Constanza; Contreras Sepúlveda, Ana María; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile
    (Oxford University Press for the Infectious Diseases Society of America, 2022) Balcells Marty, María Elvira; Le Corre Pérez, Monique Nicole; Durán Santa Cruz, Josefina Gracia; Ceballos Valdivielso, María Elena Andrea; Vizcaya Altamirano, María Cecilia; Mondaca Contreras, Sebastián Patricio; Dib Marambio, Martin Javier; Rabagliati Borie, Ricardo Miguel; Sarmiento Maldonado, Mauricio; Burgos Cañete, Paula Isabel; Espinoza Sepúlveda, Manuel Antonio; Ferres Garrido, Marcela Viviana; Martínez Valdebenito, Constanza Pamela; Ruiz-Tagle Seguel, Cinthya Grace; Ortiz Koh, Catalina Alejandra; Ross Pérez, Patricio Daniel; Budnik Bitran, Sigall; Solari Gajardo, Sandra; Vizcaya Vergara, María De Los Ángeles; Lembach, Hanns; Berríos Rojas, Roslye; Melo González, Felipe; Rios Raggio, Mariana; Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan Marcela; Nervi Nattero, Bruno
    Background Inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been widely implemented in low- and middle-income countries. However, immunogenicity in immunocompromised patients has not been established. Herein, we aimed to evaluate immune response to CoronaVac vaccine in these patients. Methods This prospective cohort study included 193 participants with 5 different immunocompromising conditions and 67 controls, receiving 2 doses of CoronaVac 8-12 weeks before enrollment. The study was conducted between May and August 2021, at Red de Salud UC-CHRISTUS, Santiago, Chile. Neutralizing antibody (NAb) positivity, total anti-SARS-CoV-2 immunoglobulin G antibody (TAb) concentrations, and T-cell responses were determined. Results NAb positivity and median neutralizing activity were 83.1% and 51.2% for the control group versus 20.6% and 5.7% (both P < .001) in the solid organ transplant group, 41.5% and 19.2% (both P < .0001) in the autoimmune rheumatic diseases group, 43.3% (P < .001) and 21.4% (PP = .001) in the cancer with solid tumors group, 45.5% and 28.7% (both P < .001) in the human immunodeficiency virus (HIV) infection group, 64.3% and 56.6% (both differences not significant) in the hematopoietic stem cell transplant group, respectively. TAb seropositivity was also lower for the solid organ transplant (20.6%; P < .0001), rheumatic diseases (61%; P < .001), and HIV groups (70.9%; P = .003), compared with the control group (92.3%). On the other hand, the number of interferon gamma spot-forming T cells specific for SARS-CoV-2 tended to be lower in all immunocompromising conditions but did not differ significantly between groups. Conclusions Diverse immunocompromising conditions markedly reduce the humoral response to CoronaVac vaccine. These findings suggest that a boosting vaccination strategy should be considered in these vulnerable patients.
  • Thumbnail Image
    Item
    Respuesta inmune humoral inducida por la vacuna influenza en niños con diagnóstico de leucemia linfoblástica aguda
    (Sociedad Chilena de Infectología, 2020) Cerda Valenzuela, Carolina Angélica; Martínez Valdebenito, Constanza Pamela; Barriga Cifuentes, Francisco José; Contreras, Marcela; Vidal, Marcela; Moreno, Rosa; Claverie, Ximena; Contreras, Paola; Huenuman, Lesly; García Salum, Tamara Cristal; Rathnasighe, Raveen; Medina Silva, Rafael Andrés; Ferrés Garrido, Marcela Viviana; Le Corre Pérez, Monique Nicole
    Background: Patients with acute lymphoblastic leukemia (ALL) have high risk of severe influenza infection and vaccination is highly recommended. The immunogenicity and effectiveness of vaccination are lower than in healthy people. Aim: To evaluate the immune response induced by influenza vaccine in children with ALL and observe effectiveness. Method: Children with ALL in maintenance phase and healthy children were recruited. Blood samples were taken at vaccination day (D0) and at day 28 (D28). Humeral response was evaluated by hemaglutination inhibition test (HAI) against H1N1. Patients were followed up for one year, clinical data and influenza episodes were recorded. Results: 34 children with ALL and 9 healthy children were included. Concerning HAI on D28, 12/34 patients and 5/8 healthy children had titers >= 1/40, with seroprotection rates of 35 and 63% respectively. Seroprotected children were older than non-seroprotected ones. During follow-up, only 3 patients non seroprotected, presented influenza infection, without oxygen supplementation or critical care support. Discussion: Children with ALL had a lower seroprotection rate than healthy children. Nevertheless, none of the seroprotected children presented influenza infection, reinforcing the annual vaccination recommendation.
  • Thumbnail Image
    Item
    SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study
    (2022) Dib Marambio, Martín Javier; Le Corre Pérez, Monique Nicole; Ortiz Koh, Catalina Alejandra; García, Daniel; Ferrés, Marcela; Martínez Valdebenito, Constanza; Ruiz-Tagle, Cinthya; Ojeda Valenzuela, María José; Espinoza Sepúlveda, Manuel Antonio; Jara Contreras, Aquiles; Arab Verdugo, Juan Pablo; Rabagliati B., Ricardo; Vizcaya Altamirano, Cecilia; Ceballos, María Elena; Sarmiento Maldonado, Mauricio; Mondaca Contreras, Sebastián Patricio; Viñuela Morales, Macarena Rocío; Pastore Thomson, Antonia; Szwarcfiter Neiman, Vania; Galdames Lavín, Elizabeth Alejandra; Barrera Vásquez, Aldo Vincent; Castro Gálvez, Pablo Federico; Gálvez Arriagada, Nicolás Marcelo Salvador; Soto Ramírez, Jorge Andrés; Bueno Ramírez, Susan; Kalergis Parra, Alexis Mikes; Nervi Nattero, Bruno; Balcells Marty, María Elvira
    Solid-organ transplant (SOT) recipients have worse COVID-19 outcomes than general population and effective immunisation in these patients is essential but more difficult to reach. We aimed to determine the immunogenicity of an mRNA SARS-CoV-2 vaccine booster in SOT recipients previously immunised with either inactivated or homologous SARS-CoV-2 mRNA vaccine. Methods: Prospective cohort study of SOT recipients under medical care at Red de Salud UC-CHRISTUS, Chile, previously vaccinated with either CoronaVac or BNT162b2. All participants received a BNT162b2 vaccine booster. The primary study end point was anti-SARS-CoV-2 total IgG antibodies (TAb) seropositivity at 8-12 weeks (56-84 days) post booster. Secondary end points included neutralising antibodies (NAb) and specific T-cell responses. Findings: A total of 140 (50% kidney, 38% liver, 6% heart) SOT recipients (mean age 54 [13.6] years; 64 [46%] women) were included. Of them, 62 had homologous (three doses of BNT162b2) and 78 heterologous vaccine schedules (two doses of CoronaVac followed by BNT162b2 booster). Boosters were received at a median of 21.3 weeks after primary vaccination. The proportion achieving TAb seropositivity (82.3% vs 65.4%, P = 0.035) and NAb positivity (77.4% vs 55.1%, P = 0.007) were higher for the homologous versus the heterologous group. On the other hand, the number of IFN-γ and IL-2 secreting SARS-CoV-2-specific T-cells did not differ significantly between groups. Interpretation: This cohort study shows that homologous mRNA vaccine priming plus boosting in SOT recipients, reaches a significantly higher humoral immune response than inactivated SARS-CoV-2 vaccine priming followed by heterologous mRNA booster.